DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 2,042 filers reported holding DANAHER CORPORATION in Q3 2023. The put-call ratio across all filers is 0.89 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $169,490 | +7.8% | 682,826 | +4.8% | 0.41% | +9.1% |
| Q2 2023 | $157,280 | -1.8% | 651,404 | +2.5% | 0.37% | -6.3% |
| Q1 2023 | $160,227 | -5.5% | 635,211 | -0.0% | 0.40% | -10.8% |
| Q4 2022 | $169,505 | -99.9% | 635,274 | -1.4% | 0.45% | -5.7% |
| Q3 2022 | $166,497,000 | +1.4% | 644,511 | -0.4% | 0.47% | +9.2% |
| Q2 2022 | $164,232,000 | -20.4% | 647,171 | -3.2% | 0.43% | +0.7% |
| Q1 2022 | $206,279,000 | -7.5% | 668,758 | -1.6% | 0.43% | -6.7% |
| Q4 2021 | $223,007,000 | +11.5% | 679,440 | +4.0% | 0.46% | -0.9% |
| Q3 2021 | $200,054,000 | +13.8% | 653,041 | -0.4% | 0.46% | +16.0% |
| Q2 2021 | $175,803,000 | +35.6% | 655,505 | +13.2% | 0.40% | +27.3% |
| Q1 2021 | $129,655,000 | +4.5% | 579,315 | +3.5% | 0.32% | +34.6% |
| Q4 2020 | $124,115,000 | +3.9% | 559,751 | +0.9% | 0.23% | -9.7% |
| Q3 2020 | $119,454,000 | +23.5% | 554,877 | +1.0% | 0.26% | +16.7% |
| Q2 2020 | $96,708,000 | +37.6% | 549,295 | +8.9% | 0.22% | +18.1% |
| Q1 2020 | $70,265,000 | -13.4% | 504,298 | -5.3% | 0.19% | +6.2% |
| Q4 2019 | $81,177,000 | +6.2% | 532,784 | +0.7% | 0.18% | -2.2% |
| Q3 2019 | $76,415,000 | +3.4% | 529,079 | +2.2% | 0.18% | +7.1% |
| Q2 2019 | $73,910,000 | +4.7% | 517,796 | -3.5% | 0.17% | -9.6% |
| Q1 2019 | $70,624,000 | +67.6% | 536,350 | +25.1% | 0.19% | +55.8% |
| Q4 2018 | $42,126,000 | -10.6% | 428,673 | -1.1% | 0.12% | +7.1% |
| Q3 2018 | $47,108,000 | -1.1% | 433,240 | -10.2% | 0.11% | 0.0% |
| Q2 2018 | $47,618,000 | -5.0% | 482,439 | -5.6% | 0.11% | -7.4% |
| Q1 2018 | $50,105,000 | +2.6% | 511,245 | -3.0% | 0.12% | +5.2% |
| Q4 2017 | $48,852,000 | +13.5% | 526,930 | +4.0% | 0.12% | +7.5% |
| Q3 2017 | $43,030,000 | +3.1% | 506,887 | +2.4% | 0.11% | -3.6% |
| Q2 2017 | $41,724,000 | -13.8% | 494,973 | -12.7% | 0.11% | -15.3% |
| Q1 2017 | $48,431,000 | +9.2% | 566,708 | -0.2% | 0.13% | +4.8% |
| Q4 2016 | $44,335,000 | -47.9% | 567,567 | -47.8% | 0.12% | +0.8% |
| Q3 2016 | $85,170,000 | +59.0% | 1,086,936 | +104.4% | 0.12% | -23.0% |
| Q2 2016 | $53,564,000 | +30.8% | 531,669 | +23.1% | 0.16% | +8.8% |
| Q1 2016 | $40,939,000 | -4.4% | 431,863 | -6.3% | 0.15% | -10.3% |
| Q4 2015 | $42,830,000 | +19.2% | 460,808 | +9.3% | 0.16% | +17.0% |
| Q3 2015 | $35,940,000 | +0.4% | 421,734 | +0.7% | 0.14% | +13.7% |
| Q2 2015 | $35,780,000 | -4.7% | 418,808 | -5.5% | 0.12% | -3.1% |
| Q1 2015 | $37,541,000 | -1.5% | 443,310 | -0.5% | 0.13% | +1.6% |
| Q4 2014 | $38,130,000 | +9.4% | 445,383 | -2.7% | 0.13% | +7.7% |
| Q3 2014 | $34,863,000 | -8.3% | 457,864 | -5.5% | 0.12% | -6.4% |
| Q2 2014 | $38,022,000 | +11.5% | 484,402 | +6.0% | 0.12% | +4.2% |
| Q1 2014 | $34,105,000 | +2.3% | 457,005 | +6.2% | 0.12% | +1.7% |
| Q4 2013 | $33,347,000 | +18.4% | 430,181 | +5.7% | 0.12% | +6.3% |
| Q3 2013 | $28,173,000 | +206.4% | 407,017 | +180.3% | 0.11% | +85.0% |
| Q2 2013 | $9,195,000 | – | 145,182 | – | 0.06% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |